Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
1(25.0%)
Phase 1
1(25.0%)
N/A
1(25.0%)
Phase 4
1(25.0%)
4Total
Phase 3(1)
Phase 1(1)
N/A(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06283784Not ApplicableCompleted

Study To Evaluate The Efficacy of a Proprietary Mix of Live Probiotics In The Prophylaxis Of Diarrhea In Adult Patients

Role: lead

NCT06252051Phase 4Completed

Effectiveness of Trivalent Influenza Vaccine (TIV) in Type 2 Diabetes Mellitus (T2DM) Patients With and Without Complications of Chronic Kidney Disease (CKD)

Role: collaborator

NCT04788355Phase 3Completed

Prevention of Complications (SARS-CoV-2): Clinical Study

Role: collaborator

NCT04407208Phase 1Completed

Convalescent Plasma Therapy in Patients With COVID-19

Role: lead

All 4 trials loaded